Trial Profile
Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Mycophenolate mofetil
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 01 Nov 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT00099749).
- 01 Nov 2011 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
- 05 Nov 2010 New trial record.